Efficacy and safety of combination therapy with GLP-1 analog lixisenatide and long-acting insulin glargine in patients with glucose intolerance or diabetes caused by hyposecretion of endogenous insulin who underwent partial pancreatectomy

Efficacy and safety of combination therapy with GLP-1 analog lixisenatide and long-acting insulin glargine in patients with glucose intolerance or diabetes caused by hyposecretion of endogenous insulin who underwent partial pancreatectomy - Efficacy and safety of combination therapy with GLP-1 analog lixisenatide and long-acting insulin glargine in patients with diabetes who underwent partial pancreatectomy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014249

Enrollment

Registered

2014-06-12

Start date

2013-12-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with glucose intolerance or diabetes caused by hyposecretion of endogenous insulin who underwent partial pancreatectomy

Interventions

From admission, pretreatment drugs were discontinued , adjust the insulin glargine dose to keep FPG100-130mg/dl. After achievement of aim FPG, start lixisenatide in addition to insulin glargine. Patie

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with glucose intolerance or diabetes caused by hyposecretion of endogenous insulin who underwent partial pancreatectomy

Exclusion criteria

Exclusion criteria: Patient for whom insulin treatment is necessary (type 1 diabetes, total pancreatectomy)

Design outcomes

Primary

Measure	Time frame
HbA1c, FPG, 1- and 2-hour PPG, CPR	—

Secondary

Measure	Time frame
Frequency of hypoglycemia , change in body weight , frepuency of Gastrointestinal disorders, visceral fat and subcutaneous fat	—

Countries

Japan

Contacts

Public ContactToru Kitazawa

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Division of Diabetes, Endocrinology and Metabolism

cickkitazawa@gmail.com03-3823-2101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026